Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Mayzent (Siponimod) Onboarding of Secondary Progressive Multiple Sclerosis (SPMS) Patients With MSGo

NCT05826028 is registered in ClinicalTrials.gov with Novartis Pharmaceuticals as lead sponsor.

NCT NCT05826028
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05826028 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Mayzent (Siponimod) Onboarding of Secondary Progressive Multiple Sclerosis (SPMS) Patients With MSGo
Lead sponsor
Novartis Pharmaceuticals
Phase
Observational
Overall status
Completed
Start date
July 9, 2020
Completion date
April 20, 2022
Enrollment
368 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

secondary progressive multiple sclerosis